By Sabela Ojea

Nurix Therapeutics said the Food and Drug Administration has granted fast-track designation for NX-5948, its treatment for certain types of lymphocytic cancer.

NX-5948 is a degrader of Bruton's tyrosine kinase and is being studied to treat relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

The clinical-stage biopharmaceutical company on Tuesday said the designation follows encouraging safety and efficacy data from its ongoing Phase 1 clinical trial.

The FDA's fast-track designation is aimed at facilitating and expediting the development and review of drug candidates.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

January 16, 2024 16:33 ET (21:33 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Grafico Azioni Nurix Therapeutics (NASDAQ:NRIX)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Nurix Therapeutics
Grafico Azioni Nurix Therapeutics (NASDAQ:NRIX)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Nurix Therapeutics